Company / Return on Equity (ROE)
Corbus Pharmaceuticals Holdings, Inc. Return on Equity (ROE) History
FY2015-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-66.0%
FY2022
5-year range
-1160.4% / -56.1%
FY2018-FY2022
Trend
+73.1%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Corbus Pharmaceuticals Holdings, Inc. reports negative total equity of -66.0% in FY2022. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-66.0% in FY2022 with a 5-year CAGR of +33.2%.
Improved from -1160.4% to -66.0% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +136.2pp
- 5-Year Change
- +33.2pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2022, return on equity (roe) increased 73.1% year-over-year.
- Peak return on equity (roe) was recorded in FY2015.
- Lowest return on equity (roe) in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -12.48 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2022 | -66.0% | +73.1% |
| FY2021 | -245.8% | +78.8% |
| FY2020 | -1160.4% | -473.7% |
| FY2019 | -202.3% | -260.5% |
| FY2018 | -56.1% | +43.5% |
| FY2017 | -99.2% | +34.3% |
| FY2016 | -151.0% | -248.4% |
| FY2015 | -43.3% | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026